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The BH3-only protein NOXA represents one of
the critical mediators of DNA-damage-induced cell
death. In particular, its involvement in cellular
responses to cancer chemotherapy is increasingly
evident. Here, we identify a strategy of cancer cells
to escape genotoxic chemotherapy by increasing
proteasomal degradation of NOXA. We show that
the deubiquitylating enzyme UCH-L1 is a key
regulator of NOXA turnover, which protects NOXA
from proteasomal degradation by removing Lys48-
linked polyubiquitin chains. In the majority of
tumors from patients with melanoma or colorectal
cancer suffering from high rates of chemoresistance,
NOXA fails to accumulate because UCH-L1 expres-
sion is epigenetically silenced. Whereas UCH-L1/
NOXA-positive tumor samples exhibit increased
sensitivity to genotoxic chemotherapy, downregula-
tion of UCH-L1 or inhibition of its deubiquitylase
activity resulted in reduced NOXA stability and resis-
tance to genotoxic chemotherapy in both human and
C. elegans cells. Our data identify the UCH-L1/NOXA
interaction as a therapeutic target for overcoming
cancer chemoresistance.INTRODUCTION
Mitochondrial apoptosis is tightly regulated by the Bcl2 protein
family comprising antiapoptotic and proapoptotic members
that are controlled by a third class of proapoptotic memberscalled BH3-only proteins. Upon intracellular stress, proapoptotic
BH3-only proteins are activated, which in turn leads to the
activation of the proapoptotic multidomain Bcl2 proteins, BAX
and BAK. This eventually results in the activation of the caspase
cascade where initiator caspases, such as caspase-9, pro-
teolytically activate executioner caspases, such as caspase-3,
and subsequent continuation of apoptosis (Youle and Strasser,
2008).
Although the role of the BH3-only protein NOXA (also called
APR/PMAIP1) in cancer development or progression is not
yet clear, its importance in cellular responses to chemo-
therapy is increasingly evident (Ploner et al., 2008). Specifically,
NOXA contributes to apoptosis in response to genotoxic
agents but also to cyclin-dependent kinase inhibitors, histone
deacetylase inhibitors (HDACis), or inhibitors of the 26S protea-
some (Ploner et al., 2008). However, the molecular mechanisms
governing NOXA levels during cellular homeostasis, cellular
stress responses, or cancer pathogenesis are not yet fully
understood. Here, we shed new light on the mechanisms gov-
erning cellular stress responses by elucidating the regulatory
mechanisms of NOXA protein abundance. Our findings offer
new opportunities for the development of effective anticancer
therapies.RESULTS
NOXA Is Subject to Posttranslational Regulation
In primary tumor samples and established tumor cell lines, we
identified a nontranscriptional control mechanism of NOXA
expression that was altered in a cohort of tumor cells (Figures
1 and S1). Specifically, by testing a number of tumor samples
including primary tumor cells derived from patients with mela-
noma (Pat1, Pat2, and Pat3) (Seeger et al., 2010), melanomaCell Reports 3, 881–891, March 28, 2013 ª2013 The Authors 881
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Figure 1. Sensitivity to Bortezomib-Induced Cell Death Is Depen-
dent on NOXA Expression
(A) Pat1, Pat2, and Pat3 tumor cells were treated with increasing concentra-
tions of bortezomib. Cell viability was measured by XTT assay after 24 hr.
(B) IB of Bcl2 protein family members in Pat1, Pat2, and Pat3 tumor cells after
bortezomib (Borte) treatment (24 hr). Actin served as a loading control.
(C) IB of NOXA expression after transfection ofPat2 tumor cells with scrambled
(scr) siRNA or three different siRNAs mapping to the NOXA mRNA (Elgendy
et al., 2011). Actin served as a loading control. Cytotoxicity was measured by
XTT assay in Pat2 cells after specific knockdown of NOXA using siNOXA1–
siNOXA3 and treatment with bortezomib (24 hr).
(D) IB and relative qPCR analyses of NOXA expression in Pat2 tumor cells
24 hr after treatment with bortezomib (25 nM) or doxorubicin (0.5 mM). ctrl,
control.
(E) IB and relative qPCR analyses of NOXA expression (normalized to Cyclo-
philin) in Pat1 versus Pat2 tumor cells. Data are presented as mean ± SEM of
three independent experiments in triplicate with statistical significance
determined by Student’s t test (left panel). Immunohistochemistry (IHC) anal-
ysis of NOXA expression in tumor sections derived from melanoma Pat1
and Pat2.
See also Figure S1.
882 Cell Reports 3, 881–891, March 28, 2013 ª2013 The Authorscell lines, HL (Hodgkin lymphoma) B cell lines (Kashkar et al.,
2003), and CRC (colorectal cancer) cell lines, a cohort of tumor
cell samples turned out to be highly sensitive to bortezomib-
mediated inhibition of the 26S proteasome (Figures 1A and
S1A). The increased susceptibility to bortezomib in primary
melanoma cells of Pat2, the Colo38 melanoma, L428 HL, and
the LS174TCRC cell lines was tightly associated with themagni-
tude of NOXA accumulation and resulted in apoptotic cell death
as shown by the processing of caspase-9 and PARP, a substrate
of active caspase-3 (Figures 1B, S1B, and S1C). In line with
previous studies (Ploner et al., 2008; Seeger et al., 2010), knock-
down of NOXA by specific siRNAs significantly reduced bortezo-
mib-induced cell death in Pat2 melanoma cells and in HeLa cell
line (Figures 1C, S1D, and S1E), underscoring the involvement of
NOXA in the cytotoxic effects of bortezomib.
Strikingly, bortezomib treatment did not significantly upregu-
late NOXA transcription, yet resulted in a tremendous accumula-
tion of NOXA protein in Pat2 melanoma cells (Figure 1D) and in
tumor cell lines exhibiting enhanced susceptibility to bortezomib
(Figure S1F). In contrast, DNA-damaging agents such as etopo-
side or doxorubicin induced a significant upregulation of NOXA
transcripts in these tumor samples, whereas NOXA protein
was not detectable (Figures 1D and S1F). Furthermore, compar-
ative measurements of NOXA mRNA and protein levels in Pat1
versus Pat2 melanoma cells revealed a remarkably high-basal
NOXA mRNA level in Pat2 melanoma cells without significantly
increasing the NOXA protein abundance as examined by
western blotting (Figure 1E, left panel). Analysis of NOXA protein
expression in tumor tissue sections of Pat1 versus Pat2 revealed
even higher NOXA protein expression in Pat1 despite consider-
ably low-NOXA mRNA level in this tumor (Figure 1E, right panel).
Similar results were obtained when NOXA mRNA level was
analyzed in further bortezomib-sensitive tumor cells including
melanoma cell lines, Colo38 and WM164, and HL cell lines,
L428 and L591 (Figure S1G). These data indicate that NOXA
protein is subject to an as-yet-unknown posttranscriptional
regulatory mechanism, which is dysregulated in a cohort of
tumor samples.
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Figure 2. Enhanced NOXA Protein Turnover
(A) FACS analysis of GFP-NOXA in Pat1–Pat2 cells transfected with indicated
amounts of DNA. GFP-NOXA expression was normalized to cotransfected
dsRed and then normalized to the 1 mg controls.
(B) Ten hours after transfection, cells were treated with 25 mg/ml cycloheximide
(CHX) for indicated time periods. GFP-NOXA expression was normalized to
cotransfected dsRed and then normalized to the t = 0 controls. Data are
presented as mean ± SEM of three independent experiments, with statistical
significance determined by Student’s t test.
(C) IB analysis of indicated proteins in HA or Myc-tag immunoprecipitates (IP)
or whole-cell lysates of 293HEK-FT cells transfectedwith HA- orMyc-NOXA or
HA- or Myc-NOXAK0.
(D) IB of HA-tag immunoprecipitation or whole-cell lysates of Pat1–Pat2 cells
transfected with HA-NOXA-WT or HA-NOXAK0.
See also Figure S2.NOXA Turnover Is Enhanced in Bortezomib-Sensitive
Tumor Samples
One possible alteration, which might be responsible for the
observed imbalance in NOXA transcript versus protein abun-
dance, is a modification in NOXA protein stability and turnover.
To examine NOXA protein stability in bortezomib-resistant
(Pat1) versus bortezomib-sensitive (Pat2) primary tumor cells,
we ectopically expressed GFP-tagged NOXA (GFP-NOXA) or
GFP-tagged BAD (GFP-BAD) as a control. In Pat1 tumor cells,
small amounts of transfected plasmid DNA were sufficient to
induce strong expression of GFP-NOXA protein. In contrast,
GFP-NOXA was barely detectable in Pat2 tumor cells even
though large amounts of plasmid DNA were transfected (Figures
2A and S2A). In contrast to GFP-NOXA, the expression levels of
GFP-BAD did not significantly differ between Pat1 and Pat2
tumor cells (Figure S2B). NOXA protein stability was further
examined by blocking de novo protein synthesis with cyclohex-
imide. GFP-NOXA, but not GFP-BAD, was found to be markedly
unstable in Pat2 compared to Pat1 tumor cells (Figures 2B and
S2C), demonstrating the rapid proteolysis of NOXA protein in
bortezomib-sensitive Pat2 tumor cells. Together, these data
indicate that in a cohort of tumor samples, the effects of elevated
NOXA transcription are countered by reduced NOXA protein
stability. Bortezomib efficiently kills these cells by disrupting
the acquired imbalance in NOXA turnover through blocking pro-
teasomal degradation of NOXA.
The ubiquitin-proteasome system (UPS) is responsible for the
degradation of cellular proteins in eukaryotic organisms and
represents a fundamental cellular quality control pathwaymodu-
lating cell fate (Vucic et al., 2011). To assess whether NOXA is
ubiquitylated prior to its degradation by the 26S proteasome,
HA-tagged NOXA (HA-NOXA) or myc-tagged NOXA (myc-
NOXA) (Figure 2C) was overexpressed in HEK293-FT cells, and
NOXA was immunoprecipitated. Subsequent immunoblot (IB)
analyses were performed with an antibody specifically detecting
K48-linked polyubiquitin chains, which represent the targeting
signal for the 26S proteasome and thus mark substrates for pro-
teasomal degradation. In line with a recent report by Baou et al.
(2010), NOXA was polyubiquitylated via K48, whereas the lysine-
lacking NOXAK0 mutant was not (Figure 2C). Furthermore, NOXA
ubiquitylation of overexpressed HA-NOXA was significantly in-
creased in Pat2 compared to Pat1 tumor cells (Figure 2D).
Loss ofUCH-L1Expression IsAssociatedwithEnhanced
NOXA Turnover
The turnover of UPS substrates is regulated by continuous ubiq-
uitylation and deubiquitylation involving E3-ubiquitin ligases and
deubiquitylating enzymes (DUBs), respectively. The presence of
more than 500 E3-ubiquitin ligases and approximately 100 DUBs
in human cells illustrates the intrinsic specificity of components
of the UPS for particular cellular substrates. Conceivably, selec-
tive manipulation of this machinery could affect the stability of
specific UPS substrates (Hoeller and Dikic, 2009; Komander
et al., 2009). To identify UPS components associated with high
versus lowNOXA protein turnover, PIQORUbiquitin-PSMicroar-
ray analyses (Miltenyi Biotec) were performed. These analyses
were carried out in primary melanoma samples (Pat1, Pat2,
and Pat3 versus nonmalignant primary melanocytes), HL celllines (HL B cell lines L428 and L591 versus a nonmalignant
control B cell line, L1309), and melanoma cell lines (bortezo-
mib-sensitive Colo38 versus bortezomib-resistant SKmel23).
The PIQOR Ubiquitin-PS Microarray is a dual-color array that
allows the analysis of mRNA expression of more than 1,300
genes presumed to be involved in UPS regulation. Here, we first
analyzed E3-ubiquitin ligases and DUBs being similarly up- or
downregulated in the tumor samples as possible candidates
responsible for enhanced NOXA ubiquitylation and turnover. A
list of the E3 ligases and the DUBs with altered expression levelsCell Reports 3, 881–891, March 28, 2013 ª2013 The Authors 883
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is presented in Table S1. Regardless of the tumor origin, the
highest correlation was observed for the ubiquitin carboxy-
terminal hydrolase-L1 (UCH-L1) (also called PARK5; PGP 9.5)
(Wilkinson et al., 1989). Remarkably, UCH-L1 was the only
DUB found to be significantly downregulated in all tumor
samples with high NOXA protein turnover (Figures 3A and
S3A). To validate the microarray analysis, UCH-L1 protein levels
were confirmed by IB (Figures 3A and S3B).
UCH-L1 Is a Specific DUB for NOXA
UCH-L1 possesses K48-dependent ubiquitin hydrolase activity
(Liu et al., 2002) and is implicated in cancer and neurological
disorders (Henderson et al., 2010). However, the substrates of
UCH-L1 and its precise function are still unknown. To investigate
whether UCH-L1 deubiquitylates and thereby stabilizes NOXA
protein levels, the abundance of myc-NOXA (Figure 3B, upper
panel) and endogenous NOXA (Figure 3B, lower panel) was
analyzed in HEK293-FT cells either in the presence of ectopically
overexpressed GFP or GFP-UCH-L1. Strikingly, the protein level
of both ectopically expressed myc-NOXA and endogenous
NOXA was significantly elevated when increasing amounts of
GFP-UCH-L1, but not GFP, were coexpressed. In contrast,
UCH-L1 expression did not interfere with endogenous PUMA,
or the NOXA antagonist MCL1, or overexpressed myc-XIAP,
which is known to be a subject of ubiquitin-dependent proteaso-
mal degradation (Figure 3B). Notably, bortezomib treatment of
cells expressing myc-NOXA without GFP-UCH-L1 resulted in
a similar increase in NOXA protein, indicating that myc-NOXA
is constitutively degraded by the proteasome unless stabilized
by UCH-L1 (Figure S3C). Furthermore, the UCH-L1-mediated
stabilization of NOXA was confirmed in primary melanoma cells.
Ectopic overexpression of UCH-L1 in Pat2 tumor cells (UCH-L1
negative) resulted in the accumulation of endogenous NOXA
protein (Figure 3C, upper panel; Figures S3D and S3E; Table
S1C). Conversely, the specific knockdown of UCH-L1 in Pat1
tumor cells (UCH-L1 positive) resulted in a marked reduction
of endogenous NOXA but did not affect the expression level
of other Bcl2 proteins, such as PUMA, BIM, or MCL1. The
unchanged expression of UCH-L3, another UCH family member
sharing 51% amino acid identity with UCH-L1 (Boudreaux et al.,Figure 3. UCH-L1 Is a Specific DUB of NOXA
(A) A selected list of DUBs identified by PIQOR Ubiquitin-PS Microarray analysis
analysis of UCH-L1 expression in whole-cell lysates derived from Pat1, Pat2, an
(B) IB analysis of indicated proteins in whole-cell lysates derived from 293HEK-
pEGFP-UCH-L1, respectively, together with myc-NOXA (upper panel), myc-XIAP
(C) Pat2 cells were transfected with GFP-UCH-L1 and stained for endogenous
(siUCH-L1), UCH-L3-specific (siUCH-L3), or unspecific scrambled siRNAs (100 p
lysates.
(D) In vitro UCH-L1/NOXA binding assay. IB analysis of the indicated proteins was
transfected with indicated expression plasmids.
(E) Cell-free binding assay of NOXA and UCH-L1. 293HEK-FT cells were transf
bortezomib for 4 hr to enrich ubiquitylated NOXA. Cell lysates were then incubate
were carried out. IB analysis for indicated proteins was performed in IPs or who
(F) Cell-free deubiquitylation assay. 293HEK-FT cells were transfected with HA-N
recombinant UCH-L3-HIS for the indicated time periods. IB analysis of indicated
(G) IB analysis of indicated proteins was performed in whole-cell lysates derived
UCH-L1C90S, or pEGFP-UCH-L1D176N together with myc-NOXA.
See also Figure S3 and Table S1.2010; Larsen et al., 1998), demonstrates the selective knock-
down of UCH-L1 (Figure 3C, lower panel). Importantly, specific
knockdown of UCH-L3 did not interfere with NOXA protein abun-
dance, demonstrating the specificity of UCH-L1 toward NOXA.
Subsequently, we provide evidence for a direct interaction of
UCH-L1 and NOXA by showing the coprecipitation of myc-
NOXA and GFP-UCH-L1 (Figure 3D). Furthermore, cell-free
binding assays were performed by incubating lysates of
HEK293-FT cells overexpressing myc-NOXA WT, myc-NOXAK0,
or myc-XIAP with either recombinant UCH-L1 or UCH-L3 (Fig-
ure 3E). Unlike UCH-L3, UCH-L1 bound NOXA but not XIAP,
confirming the specific interaction of UCH-L1 and NOXA. This
interaction is likely dependent on NOXA ubiquitylation because
barely any NOXAK0 was found to coprecipitate with UCH-L1.
The potency of UCH-L1 for hydrolyzing polyubiquitin chains
conjugated toNOXAwas further investigatedwith an in vitro deu-
biquitylation assay in lysates of bortezomib-treated HEK293-FT
cells expressing HA-NOXA (Figure 3F) or myc-NOXA (Fig-
ure S3F). In support of our hypothesis, recombinant UCH-L1
protein, but not UCH-L3, potently deubiquitylated NOXA. Addi-
tionally, UCH-L1mutantswith reduced hydrolase activity (Larsen
et al., 1996) were incapable of stabilizing myc-NOXA (Figure 3G)
or endogenous NOXA (Figure S3G). These data clearly identify
UCH-L1 as a specific DUB of NOXA that protects NOXA protein
from proteasomal degradation.
UCH-L1 Expression Correlates with Increased NOXA
Expression in Human Cancer
Given that UCH-L1 deubiquitylates and stabilizes NOXA in vitro,
tumors expressing UCH-L1 would be expected to display
elevated NOXA protein levels. Indeed, elevated expression of
UCH-L1 was closely associated with increased NOXA protein
expression in tumor tissues from 81 patients with melanoma
and 25 patients with CRC (Figures 4A, 4B, and S4D; Table S2).
Our data summarized in Figure 4B demonstrate the lack of
UCH-L1 expression in a majority of tumor samples tested
(70%). Importantly, UCH-L1 has previously been shown to be
epigenetically silenced in various tumor entities, and pharmaco-
logical unmasking approaches such as demethylating agents
and HDACis have been shown to induce UCH-L1 expressionof Pat1, Pat2, and Pat3 cells relative to primary melanocytes (upper panel). IB
d Pat3 cells (lower panel). Actin served as a loading control.
FT cells transfected with decreasing or increasing amounts of pEGFP-C3 or
(middle panel) expression plasmids, or blank (lower panel).
NOXA (red) (upper panel). Pat1 cells were transfected with UCH-L1-specific
M). After 48 hr, IB analysis of indicated proteins was performed in whole-cell
performed in GFP-tag IPs and whole-cell lysates derived from 293HEK-FT cells
ected with myc-NOXA, myc-NOXAK0, or myc-XIAP and treated with 100 nM
d with either recombinant UCH-L1-GST or UCH-L3-His (400 pM). Myc-tag IPs
le-cell lysates.
OXA. After 24 hr, cell lysates were incubated with recombinant UCH-L1-GST or
proteins was performed in HA-tag IPs or whole-cell lysates.
from 293HEK-FT cells transfected with pEGFP-C3, pEGFP-UCH-L1, pEGFP-
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Figure 4. UCH-L1 Expression Is Associated with Elevated NOXA
Protein Level in CRC and Melanoma Patient Tissues
(A) Immunohistochemical staining of UCH-L1 and NOXA in tumor sections
derived from two patients with melanoma. neg., control staining without
primary antibody.
(B) Immunohistochemical staining of UCH-L1 and NOXA in tumor sections
derived from patients with CRC (black circles) and melanoma (gray circles).
Each circle represents one patient. , no expression; +, moderate expres-
sion; ++, strong expression; +++, very strong expression.
(C) Pat2 cells were treated with increasing concentrations of Trichostatin A
(Tri A) (24 hr) or 5-aza-20-deoxycytidine (5-aza) (4 days). IB analysis of indicated
proteins was performed in whole-cell lysates. Actin served as a loading
control.
See also Figure S4 and Table S2.and promote direct cytotoxicity or in conjunction with standard
chemotherapy (Bonazzi et al., 2011; Sato et al., 2003; Yu et al.,
2008). In line with these observations, treatment of Pat2 tumor
cells with increasing concentration of the HDACi Trichostatin A
or the demethylating agent 5-aza-20-deoxycytidine resulted in
significant upregulation of UCH-L1 followed byNOXA accumula-
tion (Figure 4C). These data suggest the epigenetic silencing of
UCH-L1 as a potent tumor cell strategy to counter NOXA-driven
cytotoxicity.
UCH-L1 Controls DNA Damage-Induced Apoptosis by
Stabilizing NOXA
Our data summarized in Figure 1 showed that bortezomib effi-
ciently kills tumor cells comprising high-NOXA mRNA levels by886 Cell Reports 3, 881–891, March 28, 2013 ª2013 The Authorsdisrupting the acquired imbalance in NOXA protein turnover.
Therefore, we next examined the cytotoxic effects of UCH-L1
in UCH-L1-negative Pat2 tumor cells (high NOXA mRNA and
reduced NOXA stability). Accordingly, ectopic overexpression
of GFP-UCH-L1 or microinjection of recombinant UCH-L1 pro-
tein resulted in apoptosis of Pat2 tumor cells as monitored by
the activation of the executioner caspase-3 (Figure S4B) or the
exposure of phosphatidyl serine (Figure S4C), respectively.
Furthermore, ectopic overexpression of UCH-L1 only in conjunc-
tion with the coexpression of subtoxic concentrations of myc-
NOXA was capable to induce significant apoptotic cell death
of HeLa cells (Figure S4A). These data underscore the central
role of NOXA in UCH-L1-mediated cell death.
NOXA has previously been implicated in mediating genotoxic
stress-induced apoptosis (Oda et al., 2000; Villunger et al.,
2003). Accordingly, specific knockdown of NOXA, but not
BAD, significantly reduced doxorubicin-induced cell death in
Pat1 tumor cells and HeLa cell line (Figure S5A). Congruently,
specific knockdown of UCH-L1 in UCH-L1-positive Pat1 tumor
cells significantly reduced the sensitivity to DNA damage-
induced cell death accompanied by the lack of NOXA accumu-
lation (Figure 5A). Similar effects were observed when the
enzymatic activity of UCH-L1 was inhibited in Pat1 tumor cells
using LDN-57444, a specific inhibitor of UCH-L1 (Liu et al.,
2003) (Figure S5C). In this matter, the lack of UCH-L1 in bortezo-
mib-sensitive (high NOXA mRNA and low NOXA stability)
(Figures 1 and S1) tumor samples was associated with reduced
sensitivity toward DNA-damaging agents (Figures 5B and S5B).
These data strongly indicate that UCH-L1 potentiates DNA
damage-induced cell death by stabilizing NOXAprotein. Accord-
ingly, the specific knockdown of UCH-L1, but not UCH-L3, in
HeLa cells reduced sensitivity to genotoxic treatments that effi-
ciently upregulate NOXA transcription (Figure 5A, lower panel).
In contrast, UCH-L1 knockdown did not significantly affect
cell death in response to bortezomib (Figure 5A, lower panel),
which primarily does not upregulate NOXA transcription (Figures
1 and S1).
Caenorhabditis elegans represents an ideal in vivo model to
study cellular DNA damage response (Gartner et al., 2000; Ster-
giou and Hengartner, 2004). DNA damage induced by ionizing
radiation (IR) initiates several cellular responses in C. elegans,
including germ cell apoptosis. On the other hand, dysfunction
of DNA damage-responsive genes has been shown to enhance
embryonic lethality upon IR and genomic instability (Gartner
et al., 2000). The C. elegans UCH-L1 homologs ubh-1, ubh-2,
or ubh-3 exhibit more than 70% identity, suggesting a high
functional redundancy within the protein family. Moreover, the
three ubh genes are organized in one operon structure on chro-
mosome V under the control of the same promoter. Conse-
quently, specific knockdown of a single ubh gene product
results in simultaneous downregulation of all family members
with maximal phenotypic outcome. To study the impact of the
C. elegans UCH-L1 homolog on DNA damage-induced germ
cell apoptosis, the ubh gene products were downregulated by
ubh-2 RNAi or ubh-3 RNAi, and germ cell apoptosis was quanti-
fied after exposure to IR. Specific knockdown of eel-1, the
C. elegans homolog of MULE (MCL-1 ubiquitin ligase) (Zhong
et al., 2005), which has recently been shown to be required in
DNA damage-induced germ cell apoptosis (Ross et al., 2011),
was used as a control. Similar to eel-1, ubh-2 and ubh-3 RNAi
resulted in reduced apoptosis and embryonic hypersensitivity
to IR (Figures 5C and S5D) without interfering with the tran-
scriptional activation of the C. elegans BH3-only protein egl-1
(Conradt and Horvitz, 1998) upon genotoxic stress (Figure S5F).
In contrast, single ubh-1 deletion mutants revealed no obvious
alteration in DNA damage-induced lethality (Figure S5E), which
further supports the idea of functional redundancy between
the UCH-L1 homolog in C. elegans. Together with the data
obtained in model cell lines and primary tumor tissues, these
data indicate an evolutionarily conserved role of UCH-L1 in
DNA damage-induced apoptosis by posttranslational control
of NOXA.
DISCUSSION
The present data show that UCH-L1 is an important com-
ponent of the DNA damage response and impacts on the
susceptibility of cancer cells toward chemotherapy by stabi-
lizing NOXA. DNA damage usually results in the transcriptional
upregulation of NOXA. NOXA protein is immediately marked
for proteasomal degradation with K48-polyubiqutin chains by
an as yet unknown ubiquitin ligase. In UCH-L1-positive cells,
UCH-L1 deubiquitylates and stabilizes NOXA resulting in
NOXA-triggered cell death. In contrast, in cells lacking UCH-
L1, transcriptionally upregulated NOXA is markedly unstable
as a result of continuous ubiquitylation and subsequent degra-
dation by the UPS. Accordingly, DNA damage-inducing chemo-
therapy does not result in a sufficient accumulation of NOXA
protein and thus does not induce cell death in chemoresistant
tumor cells (Figure 5D).
Protein ubiquitylation is central to maintain genome stability
and to regulate cellular response mechanisms such as cell-cycle
arrest and apoptosis (Eldridge and O’Brien, 2010). In fact, recent
studies using proteasome inhibitors validated the UPS as a ther-
apeutic target in cancer (Orlowski and Kuhn, 2008) and provided
an impetus to continue the development of novel drugs that
more specifically and effectively interfere with the UPS. In this
regard, our data demonstrate the dynamic regulation of NOXA
protein expression by the UPS in response to chemotherapy.
By identifying UCH-L1 as the specific NOXA-DUB, our study
sheds new light on the question as to how tumor cells escape
apoptosis and resist chemotherapy. Loss of UCH-L1 in chemo-
resistant cancer gives rise to increased NOXA ubiquitylation,
reduced NOXA stability, and inefficient apoptosis in response
to genotoxic stress (Figure 5D).
NOXA as a specific antagonizer ofMCL1 is an important deter-
minant of cell death and chemosensitivity in cancer (Elgendy
et al., 2011; Ploner et al., 2008; Shibue et al., 2006). Remarkably,
MCL1 protein was recently found to be controlled by the UPS
and interfere with chemotherapy (Schwickart et al., 2010; Wertz
et al., 2011). Thus, two essential regulators of mitochondrial
apoptosis are specifically controlled by the UPS, which in turn
determine the therapeutic response to anticancer treatments.
Understanding the specific link between the apoptoticmachinery
and the UPS will promote the development of new therapeutic
strategies to overcome chemoresistance in cancer.EXPERIMENTAL PROCEDURES
Cell Culture, Cytotoxic Treatments, and Cell Viability
The establishment and maintenance of the following cells and cell lines have
been described previously: L428, L591, L1309 (Kashkar et al., 2002), MeWo
(Seeger et al., 2010), SKmel23, MV3, WM164, SKmel28 (Zigrino et al., 2005),
Colo38 (Giacomini et al., 1986), and primary melanoma cells derived from
Pat1 (HOM1), Pat2 (HM1), and Pat3 (MOO1) (Schmidt et al., 2011). HEK293-
FT cells were from ATCC (CRL-11268; Rockville, MD, USA) and maintained
according to the manufacturer’s instructions.
Cells were treated with etoposide, doxorubicin, Trichostatin A, cisplatin,
LDN-57444 (Sigma-Aldrich), or bortezomib (Teva) and incubated for the indi-
cated periods.
Cell viability was measured using Cell Proliferation Kit II (XTT; Roche) and
where indicated by trypan blue exclusion using an automated cell counter
(Countess; Invitrogen).
qPCR
Total RNA was isolated using the standard phenol/chloroform method. cDNA
was synthesized by cDNA First-Strand Aid Kit (Fermentas) using polyT primers
according to the manufacturer’s instructions. qPCR after treatment with borte-
zomib, doxorubicin, or etoposide was performed with specific primers for
NOXA (forward 50-gctccagcagagctggaagt-30; reverse 50-ccatct tccgtttccaa
gggc-30) and normalized to GAPDH (forward 50-ggtatcgtggaaggact-30; reverse
50-gggtgtcgctgttgaa-30). For the analyses of basal NOXA mRNA, suitable
housekeeping genes were selected after alignment of mRNA expression in
the different tumor entities using BioGPS (http://biogps.org). A comparable
mRNA expression level was found for TAP1 (forward 50-gcagctcatggag
aaaaagg-30; reverse 50-gaaaagggagggagatggag-30), TAP2 (forward 50-aggagg
ctgcttcacct aca-30; reverse 50-tgagttcagctcccctgtct-30), OAS1 (forward 50-
acaggcagaagaggactgga-30; reverse 50-ggatcaa gagtcccacctga-30), OAS2
(forward 50-gcaccaataccccctacctt-30; reverse 50-tgcgccattctttgttagtg-30),
CD80 (forward 50-gcacatctcatggcagctaa-30; reverse 50-cacaggagcaaggttt
gtga-30), and Cyclophilin D (forward 50-ctaggcatgg gaggc-30; reverse 50-
ctcgaataagtttgacttgtgttt-30). qPCR for the analyses of egl-1 expression after
Gy in C. elegans was performed with specific primers for egl-1 (forward 50-
tactcctcgtctcaggactt-30; reverse 50-catcgaagtcatcgcacat-30 ) and normalized
to g-tubulin (tbg-1) (forward 50-cgtcatcagcctggtagaaca-30; reverse 50-tgat
gactgtccacgttgga-30). qPCR was performed using SYBR Green Mix (Roche
Applied Sciences) with a 96-well-plate Multicolor Real-Time PCR Detection
System (iQ5; Bio-Rad), and data were further evaluated using the standard
Pfaffel method.
Plasmids and siRNA-Mediated Knockdown
NOXA-WT, NOXA-K0 cDNA was obtained from Addgene and subcloned in
pCDNA-3.1+ (Invitrogen) containing amino-terminal HA or myc sequence
(HA/myc-NOXA WT; HA/myc-NOXA-K0) or in pEGFP-C3 (Clontech) (GFP-
NOXA). Myc-UCH-L1 cDNA was a kind gift from Professor K-J Lee (Ewha
Womans University, Seoul, Korea) and subcloned in pEGFP-C3 (GFP-UCH-
L1). UCH-L1D176N and UCH-L1C90S constructs were obtained by site-directed
mutagenesis PCR. Myc-XIAP has been described previously (Kashkar et al.,
2007). BAD was amplified from HeLa cDNA and subcloned in pEGFP-C3
(Clontech) (GFP-BAD).
For siRNA-mediated knockdown, Pat1–Pat2 and HeLa cells were trans-
fected with LTX2000 (Invitrogen) with specific siRNAs for NOXA (siNOXA1
sense, 50-ggugcacguuucaucaauu-30; siNOXA2 sense, 50-ccggacauaacugugg
uuc-30; siNOXA3 sense, 50-gcugugauaacgugaaacc-30), BAD (sense, 50-guac
uucccucaggccuau-30), PUMA (sense, 50-ccaucucaggaaaggcugutt-30), UCH-
L1 (sense, 50-gcacaaucggacuuauucatt-30), UCH-L3 (sense, 50-ggcaauucguu
gauguauatt-30), or unspecific 647-scr (Allstar neg.; QIAGEN).
Sample Preparation and IB
Cell and nuclear extracts were prepared as described previously (Kashkar
et al., 2007). Western blots were performed with antibodies recognizing
NOXA (OP180; Calbiochem), BIM (#2933; Cell Signaling), BAD (#9239;
Cell Signaling), PUMA (#4976; Cell Signaling), Actin, PARP (AM30; Calbio-
chem), caspase-9 (#9502; Cell Signaling), ubiqutinK48-specific (clone Apu2;Cell Reports 3, 881–891, March 28, 2013 ª2013 The Authors 887
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Millipore), UCH-L1 (#3524; Cell Signaling), MCL1 (#4572; Cell Signaling), and
UCH-L3 (#3525; Cell Signaling).
Immunoprecipitations
HEK293-FT cells were transfected using the standard CaPO4method; primary
melanoma cells were transfected using LTX-2000 (Invitrogen). For the detec-
tion of ubiquitylated tagged NOXA in HEK293-FT cells, cells were denaturated
prior to immunoprecipitation. Cells were lysed in 100 ml lysis buffer (150 mM
NaCl, 1% Triton X-100, 50 mM Tris HCl [pH 8.0]) containing 1% SDS and
boiled for 30 min. The lysate was diluted with lysis buffer to obtain a final
SDS concentration of 0.1%, and HA- or myc-tagged protein immunoprecipita-
tionwas performed bymagnetic epitope labeling and separation using mMACS
Epitope Tag Protein Isolation Kit (Miltenyi Biotech), according to the manufac-
turer’s instructions. Due to restricted material, Pat1–Pat2 cells were directly
diluted in lysis buffer, and tag-specific immunoprecipitation was performed
without prior denaturation.
For the detection of ubiquitylated proteins, columns were washed 63 with
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris HCl (pH 8.0), and 13 with 20 mM Tris HCl (pH 7.5). For binding assays,
columns were washed 33 with lysis buffer.
NOXA Protein Stability Assays
Pat1–Pat2 cells were transfected with GFP-NOXA or GFP-BAD and dsRed
with LTX2000 (Invitrogen). Cells were fixed with 3% paraformaldehyde and
analyzed by flow cytometry (FACSCalibur; BD) and further evaluated with
FlowJo. Relative GFP-NOXA or GFP-BAD or dsRed expression of transfected
cells was assessed using FITC-median or PE-Median, respectively. Values
represent fold induction of NOXA or BAD expression to control sample.
Each sample was normalized to fold induction of dsRed expression to account
for possible differences in transfection efficiency.
In Vitro Deubiquitylation and Binding Assays
HEK293-FT cells were transfected with HA-NOXA or myc-NOXA using CaPO4
and treated for 24 hr with 100 nM bortezomib. Eight hours posttransfection,
cells were washed twice with PBS and mechanically pulped in deubiquityla-
tion assay buffer (50 mM HEPES/NaOH [pH 7.8], 0.5 mM EDTA, 1 mM DTT,
0.1 mg/ml ovalbumin). Equal amounts were incubated with 400 pM recombi-
nant UCH-L1-GST or UCH-L3-His (Enzo Life Sciences) at 25C. The lysate
was diluted 1:10 with lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM
Tris HCl [pH 8.0]) to reduce the DTT concentration to 0.1 mM prior to
immunoprecipitation.
Microscopy
Cells were transfected with indicated plasmids and fixed in 3% paraformalde-
hyde 24 hr posttransfection. NOXA (OP180; Calbiochem unless indicated
otherwise) or active caspase-3 (clone 5A1E #9664; Cell Signaling) was stained
with secondary Alexa Fluor 568 anti-mouse (A21207, Molecular Probes or
Alexa Fluor 594 anti-rabbit [#A11019 Molecular Probes], respectively). NucleiFigure 5. UCH-L1 Impacts on DNA Damage-Induced Apoptosis
(A) Pat1 tumor cells were transfected with siUCH-L1 or scr siRNAs (100 pM). After
indicated proteins was performed in whole-cell lysates. Actin served as a loading
HeLa cells were transfected with UCH-L1-specific (siUCH-L1), UCH-L3-speci
measured by XTT assay after treatment with doxorubicin (1 mM, 24 hr), etoposide
(lower panel). Data are presented as mean ± SEM of three independent experim
(B) IB analysis of UCH-L1 expression in whole-cell lysates derived from Pat1, Pat2
a loading control. Cells were treated with bortezomib (50 nM), doxorubicin (2 mM
presented as mean ± SEM of three independent experiments (lower panels).
(C) Synchronized L1 worms were depleted for the indicated gene products by RN
were quantified 36 hr after treatment. Data are presented as mean ± SEM from
mined by Student’s t test. DIC pictures were taken 36 hr after IR. Arrowheads in
(D) Schematic illustration of howUPS and UCH-L1 controls NOXA turnover and ch
transcriptional upregulation of NOXA. By an as-yet-unknown E3 ligase, NOXA ge
and liberated NOXA is able to trigger apoptosis. In UCH-L1-negative cells, ubiqui
to induce mitochondrial apoptosis.
See also Figure S5.were stainedwithDAPI (Molecular Probes). Cells were analyzedby amotorized
inverted microscope (Olympus Ix81; Tokyo).
For microinjection experiments, cells were seeded on glass-bottom dishes
and cultured in VLE-RPMI Medium containing 1% penicillin streptomycin,
10% FCS, 2.5 mM CaCl2, 20 mM HEPES, 0.5% AnnexinV-FITC (BD
PharMingen). Recombinant proteins were injected together with 3% TRITC-
dextran (Sigma-Aldrich) using a FemtoJet microinjector (Eppendorf). Live-
cell imaging after microinjection was performed using confocal microscopy
(Olympus; FluoView 1000).
Tissue Immunostaining
Paraffin sections (6 mm) were first deparaffinized by xylol and ethanol
incubations and washed in TBS. Sections were blocked for 1 hr with 10%
FCS in TBS before applying the primary antibodies to NOXA (Abcam
36833, 1:500) and UCHL-1 (Acris 1673P, 1:40) and secondary HRP-labeled
anti-rabbit polymer (Dako Envision; Dako). Bound antibodies were detected
with AEC substrate (Dako) and nuclei stained with hematoxylin (Thermo
Scientific). Specimens of human stomach were used as positive control for
both antibody stainings (kindly provided from the local Department of
Pathology); negative controls were performed by omitting primary specific
antibodies.
C. elegans Germ Cell Apoptosis and Embryonic Hypersensitivity
RNAi experiments were conducted as described previously by Timmons et al.
(2001) in wild-type (Bristol strain N2) and mutant strains (LG4, rad-51, ubh-1
[ok2218] IV/nT1[qls51]) provided by the C. elegans Reverse Genetics Core
Facility at the University of British Columbia. Bacteria (E. coli HT115[De3])
harboring different RNAi-feeding constructs were seeded on NGM plates con-
taining 1 mM IPTG and 50 mg/ml ampicillin. For control experiments, an empty
vector (L4440) or a vector depleting for a GFP gene product was used. On
these plates synchronized L1-stage C. elegans hermaphrodites were grown
at 20C.
L4-stage hermaphrodites were irradiated with the corresponding IR
dose (Acs et al., 2011). Apoptotic germ cell corpses were scored as
described previously by Gumienny et al. (1999). Embryonic survival was
assessed with a radiation-sensitivity assay as described previously by Acs
et al. (2011).
ACCESSION NUMBERS
The GEO accession number for the PIQOR Ubiquitin-PS microarray data
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SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2013.02.014.24 hr, cells were treated with doxorubicin (Dox) (2 mM) for 24 hr. IB analysis for
control (upper panel). Cytotoxicity was measured by XTT assay (middle panel).
fic (siUCH-L3), or unspecific scrambled siRNAs (100 pM). Cytotoxicity was
(Eto) (50 mM, 24 hr), cisplatin (Cis) (100 mM, 24 hr), or bortezomib (50 nM, 48 hr)
ents, with statistical significance determined by Student’s t test.
, and Pat3 cells (left panel) or melanoma cell lines (right panel). Actin served as
), or cisplatin for 24 hr, and cytotoxicity was measured by XTT assay. Data are
Ai. L4 worms were then exposed to 0, 30, or 60 Gy of IR, and germ cell corpses
three independent experiments (n = 25–50), with statistical significance deter-
dicate apoptotic corpses in the pachytene zone of the germline.
emosensitivity in cancer. DNA damage induced by chemotherapy results in the
ts polyubiquitylated. In UCH-L1-positive cells, UCH-L1 deubiquitylates NOXA,
tylated NOXA is continuously degraded by the proteasome and thus is not able
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